<DOC>
	<DOCNO>NCT02497157</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety fluorouracil ( 5-FU ) , levofolinate calcium ( l-LV ) , oxaliplatin ( L-OHP ) irinotecan hydrochloride hydrate ( CPT-11 ) ( FOLFOXIRI ) plus bevacizumab untreated metastatic colorectal cancer patient harbor Uridine diphosphate ( UDP ) -glucuronosyl transferase 1A1 ( UGT1A1 ) *1/*1 , *1/*6 *1/*28 .</brief_summary>
	<brief_title>Bevacizumab + Triplet Treatment Untreated With Chemotherapy Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>1 . Histologically confirm adenocarcinoma colon rectum . 2 . Unresectable recurrent colorectal cancer patient . 3 . One measurable lesion RECIST ver.1.1 criterion . 4 . No prior chemotherapy , immunotherapy , radiotherapy . 5 . Life expectancy least 3 month . 6 . Patients harbor UGT1A1*1/*1 , *1/*6 *1/*28 . 7 . The Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 1 . 8 . Vital organ function ( list ) preserve within 14 day prior entry . White blood cell count ( WBC ) : &gt; = 3,000 per cubic millimeter Neu : &gt; = 1,500 per cubic millimeter Platelet count ( PLT ) : &gt; = 100,000 per cubic millimeter Aspartate aminotransferase ( AST/GOT ) alanine aminotransferase ( ALT/GPT ) : &lt; = 100 IU/L , &lt; = 150 IU/L case liver metastasis Tbil : &lt; = 1.5 mg/dL Serum creatinine : &lt; = 1.50 mg/dL Proteinuria : &lt; = 1+ Prothrombin timeinternational normalize ratio ( PTINR ) : &lt; 1.5 9 . Written informed consent . 1 . Vermiform appendix cancer anal canal cancer . 2 . Administration blood products/ granulocytecolony stimulate factor ( GCSF ) , blood transfusion within 14 day prior enrollment . 3 . Synchronous multiple malignancy metachronous multiple malignancy le 5 year disease free interval . 4 . Hepatitis B virus antigen ( HBsAg ) ( + ) , hepatitis C virus antibody ( HCVAb ) ( + ) . 5 . History severe allergy . 6 . Sensory alteration paresthesia interfere function . 7 . Prior radiotherapy ilium abdomen . 8 . Infectious disease . 9 . Uncontrolled diarrhea . 10 . Ileus bowel obstruction . 11 . Interstitial lung disease pulmonary fibrosis . 12 . Malignant coelomic fluid require drainage . 13 . Administration atazanavir sulfate . 14 . Heart disease clinically problem . 15 . Major surgical procedure intestinal resection within 28 day prior enrollment colostomy within 14 day prior enrollment . 16 . Known brain metastasis strongly suspect brain metastasis . 17 . History thromboembolic disease . 18 . Receiving antiplatelet drug . 19 . Poorly control gastrointestinal ulcer . 20 . History intestinal perforation within past 12 month . 21 . Poorly control hypertension . 22 . Poorly control diabetes mellitus . 23 . Severe mental disorder . 24 . Women pregnant nursing , men woman wish conceive child intention contraception . 25 . Any case regard inadequate study enrollment investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>bevacizumab</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>irinotecan</keyword>
	<keyword>hydrochloride hydrate</keyword>
	<keyword>fluorouracil</keyword>
	<keyword>levofolinate calcium</keyword>
</DOC>